Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
entities : Cns pharmaceuticals, inc. symbols : RETA save search
CNS Pharmaceuticals Achieves Completion of Planned Enrollment in Potentially Pivotal Study of Berubicin for the Treatment of Glioblastoma Multiforme (GBM)
Published: 2024-01-17 (Crawled : 14:30) - biospace.com/
CNSP | News | $0.209 -0.48% 35K
|
Health Technology
|
| O: 5.82%
H: 7.57%
C: -7.32%
berubicin treatment pharmaceuticals glioblastoma study
CNS Pharmaceuticals (NASDAQ: CNSP) Presents Updated Safety Data from Ongoing Potentially Pivotal Study Evaluating Berubicin in Advance of the Pre-Planned Interim Analysis of Efficacy
Published: 2023-11-22 (Crawled : 15:00) - biospace.com/
CNSP | News | $0.209 -0.48% 35K
|
Health Technology
|
| O: 3.35%
H: 25.0%
C: 4.17%
berubicin ongoing pharmaceuticals study
CNS Pharmaceuticals' (NASDAQ:CNSP) Ongoing Potentially Pivotal Study of Berubicin for the Treatment of Glioblastoma Multiforme (GBM) Continues Rapid Pace of Enrollment with 229 Patients Enrolled to Date
Published: 2023-10-11 (Crawled : 13:00) - biospace.com/
CNSP | News | $0.209 -0.48% 35K
|
Health Technology
|
| O: -2.8%
H: 18.26%
C: 13.46%
rapid berubicin treatment ongoing glioblastoma study
CNS Pharmaceuticals (NASDAQ: CNSP) Presents Updated Results from On-Going Potentially Pivotal Study of Berubicin in Adult Patients with Recurrent GBM (WHO Grade IV) After Failure of Standard First Line Therapy
Published: 2023-08-14 (Crawled : 13:00) - biospace.com/
RETA | $172.36 0.02% 0.03% 0
|
Health Technology
|
| O: 0.31%
H: 1.04%
C: 0.76%
CNSP | News | $0.209 -0.48% 35K
|
Health Technology
|
| O: -2.46%
H: 2.53%
C: -10.61%
berubicin pharmaceuticals therapy results study
CNS Pharmaceuticals Provides Clinical Trial Update for Ongoing Potentially Pivotal Study with Berubicin for the Treatment of Glioblastoma Multiforme (GBM)
Published: 2023-08-03 (Crawled : 12:20) - biospace.com/
RETA | $172.36 0.02% 0.03% 0
|
Health Technology
|
| O: 0.07%
H: 0.83%
C: 0.57%
CNSP | News | $0.209 -0.48% 35K
|
Health Technology
|
| O: 0.93%
H: 3.24%
C: 1.39%
berubicin update treatment ongoing pharmaceuticals trial glioblastoma study
CNS Pharmaceuticals (NASDAQ:CNSP) Achieves Over 50% Completion of Enrollment in Potentially Pivotal Study with Berubicin for the Treatment of Glioblastoma Multiforme (GBM)
Published: 2023-05-25 (Crawled : 20:00) - biospace.com/
RETA | $172.36 0.02% 0.03% 0
|
Health Technology
|
| O: -0.18%
H: 0.79%
C: -2.78%
CNSP | News | $0.209 -0.48% 35K
|
Health Technology
|
| O: -4.52%
H: 6.84%
C: 4.74%
berubicin treatment pharmaceuticals glioblastoma study
Over 100 Patients Now Enrolled in CNS Pharmaceuticals’ (NASDAQ: CNSP) Potentially Pivotal Study Evaluating Berubicin for the Treatment of Glioblastoma Multiforme (GBM)
Published: 2023-04-10 (Crawled : 16:00) - biospace.com/
RETA | $172.36 0.02% 0.03% 0
|
Health Technology
|
| O: -1.23%
H: 1.81%
C: 1.25%
CNSP | News | $0.209 -0.48% 35K
|
Health Technology
|
| O: -4.79%
H: 8.16%
C: 4.9%
berubicin treatment 100 glioblastoma study
CNS Pharmaceuticals Receives Approval from Competent Authority and Central Ethics Committee in Italy for Potentially Pivotal Global Trial Evaluating Berubicin for the Treatment of GBM
Published: 2023-04-06 (Crawled : 14:20) - biospace.com/
RETA | $172.36 0.02% 0.03% 0
|
Health Technology
|
| O: 0.79%
H: 0.86%
C: 0.6%
CNSP | News | $0.209 -0.48% 35K
|
Health Technology
|
| O: 53.58%
H: 6.02%
C: -43.6%
approval berubicin treatment pharmaceuticals global trial
CNS Pharmaceuticals Continues Momentum in Ongoing Potentially Pivotal Global Trial Evaluating Berubicin for the Treatment of GBM with First Patient Enrolled in Switzerland
Published: 2023-03-09 (Crawled : 14:20) - prnewswire.com
RETA | $172.36 0.02% 0.03% 0
|
Health Technology
|
| O: -2.68%
H: 5.52%
C: 3.54%
CNSP | News | $0.209 -0.48% 35K
|
Health Technology
|
| O: -2.72%
H: 4.3%
C: -5.59%
treatment ongoing pharmaceuticals global trial berubicin momentum switzerland
CNS Pharmaceuticals Announces First Patient Enrolled in Spain in Ongoing Potentially Pivotal Global Trial Evaluating Berubicin for the Treatment of GBM
Published: 2023-02-07 (Crawled : 14:00) - prnewswire.com
RETA | $172.36 0.02% 0.03% 0
|
Health Technology
|
| O: 0.0%
H: 0.64%
C: -0.91%
CNSP | News | $0.209 -0.48% 35K
|
Health Technology
|
| O: -1.49%
H: 5.19%
C: -6.49%
treatment ongoing pharmaceuticals global trial berubicin
CNS Pharmaceuticals Announces Investigator-Initiated Phase 1b/2 Trial to be Conducted at the Pomeranian Medical University in Poland
Published: 2023-01-12 (Crawled : 14:00) - prnewswire.com
RETA | $172.36 0.02% 0.03% 0
|
Health Technology
|
| O: -0.22%
H: 3.54%
C: 2.81%
CNSP | News | $0.209 -0.48% 35K
|
Health Technology
|
| O: -2.21%
H: 5.66%
C: -6.04%
pharmaceuticals medical trial phase 2b
CNS Pharmaceuticals Announces Preliminary Results from Ongoing Potentially Pivotal Trial Evaluating Berubicin for the Treatment of Recurrent Glioblastoma Multiforme (GBM)
Published: 2022-12-08 (Crawled : 15:00) - biospace.com/
RETA | $172.36 0.02% 0.03% 0
|
Health Technology
|
| O: 0.34%
H: 1.98%
C: -1.85%
CNSP | News | $0.209 -0.48% 35K
|
Health Technology
|
| O: 2.92%
H: 0.03%
C: -3.66%
treatment ongoing pharmaceuticals trial berubicin glioblastoma
CNS Pharmaceuticals Announces Dosing of First Patient in Europe/France in Ongoing Potentially Pivotal Global Trial Evaluating Berubicin for the Treatment of GBM
Published: 2022-11-02 (Crawled : 13:00) - biospace.com/
RETA | $172.36 0.02% 0.03% 0
|
Health Technology
|
| O: -0.72%
H: 4.93%
C: 0.24%
CNSP | News | $0.209 -0.48% 35K
|
Health Technology
|
| O: 5.88%
H: 15.28%
C: 11.0%
treatment ongoing pharmaceuticals global trial berubicin
CNS Pharmaceuticals Announces Activation of First Clinical Trial Sites in Europe for Ongoing Potentially Pivotal Global Trial Evaluating Berubicin for the Treatment of GBM
Published: 2022-09-28 (Crawled : 13:20) - prnewswire.com
RETA | $172.36 0.02% 0.03% 0
|
Health Technology
|
| O: 2.2%
H: 9.44%
C: 6.58%
CNSP | News | $0.209 -0.48% 35K
|
Health Technology
|
| O: -4.79%
H: 9.94%
C: 7.79%
treatment europe ongoing pharmaceuticals global trial berubicin
CNS Pharmaceuticals Receives Approval from U.S. FDA for Protocol Amendment to Ongoing Potentially Pivotal Global Trial Evaluating Berubicin for the Treatment of GBM
Published: 2022-06-23 (Crawled : 13:20) - biospace.com/
RETA | $172.36 0.02% 0.03% 0
|
Health Technology
|
| O: -0.09%
H: 3.99%
C: 3.0%
CNSP | News | $0.209 -0.48% 35K
|
Health Technology
|
| O: 32.07%
H: 1.89%
C: -24.85%
treatment fda ongoing trial approval berubicin potential
CNS Pharmaceuticals Announces Presentation of Ongoing Potentially Pivotal Berubicin Clinical Trial Design at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting
Published: 2022-06-08 (Crawled : 13:00) - biospace.com/
RETA | $172.36 0.02% 0.03% 0
|
Health Technology
|
| O: -1.36%
H: 6.26%
C: 1.73%
CNSP | News | $0.209 -0.48% 35K
|
Health Technology
|
| O: 0.98%
H: 3.23%
C: -0.9%
ongoing trial presentation berubicin potential designation
CNS Pharmaceuticals Announces Acceptance of Abstract for Poster Presentation at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting
Published: 2022-05-18 (Crawled : 17:00) - biospace.com/
RETA | $172.36 0.02% 0.03% 0
|
Health Technology
|
| O: -4.6%
H: 6.23%
C: 2.33%
CNSP | News | $0.209 -0.48% 35K
|
Health Technology
|
| O: -6.49%
H: 14.87%
C: 7.96%
presentation
CNS Pharmaceuticals Receives Approval from Ethics Committee and Competent Authority in Spain for Potentially Pivotal Study of Berubicin for the Treatment of Glioblastoma Multiforme (GBM)
Published: 2022-04-28 (Crawled : 19:00) - biospace.com/
RETA | $172.36 0.02% 0.03% 0
|
Health Technology
|
| O: 2.2%
H: 0.68%
C: -0.26%
CNSP | News | $0.209 -0.48% 35K
|
Health Technology
|
| O: 8.65%
H: 0.0%
C: -6.34%
treatment approval berubicin potential glioblastoma
CNS Pharmaceuticals Receives Approval from France Ethics Committee and Competent Authority for Potentially Pivotal Study of Berubicin for the Treatment of Glioblastoma Multiforme (GBM)
Published: 2022-04-06 (Crawled : 13:00) - biospace.com/
RETA | $172.36 0.02% 0.03% 0
|
Health Technology
|
| O: -1.09%
H: 1.8%
C: 0.45%
CNSP | News | $0.209 -0.48% 35K
|
Health Technology
|
| O: 5.16%
H: 7.69%
C: 6.16%
treatment approval berubicin potential glioblastoma
CNS Pharmaceuticals Receives Approval from Competent Authority of Switzerland for Potentially Pivotal Study of Berubicin for the Treatment of Glioblastoma Multiforme (GBM)
Published: 2022-04-05 (Crawled : 14:00) - biospace.com/
RETA | $172.36 0.02% 0.03% 0
|
Health Technology
|
| O: 0.63%
H: 1.09%
C: -2.15%
CNSP | News | $0.209 -0.48% 35K
|
Health Technology
|
| O: 0.24%
H: 29.56%
C: 14.4%
treatment approval berubicin switzerland potential glioblastoma
Gainers vs Losers
| 58% | 42% |
Top 10 Gainers
CZOO | $10.52 110.82% 10M
|
CSSE 4 | $0.3181 108.86% 170M
|
Consumer Services
BOF | $1.88 60.68% 98M
|
AMST | $3.1 55.0% 66M
|
Technology Services
LICN | $0.85 51.79% 13M
|
WIMI | $1.03 41.99% 15M
|
Technology Services
SKIL 4 | $8.045 40.89% 230K
|
Information
MULN | News | $3.805 39.38% 11M
|
Information
RILY | $30.01 38.17% 11M
|
Finance
MTC | $3.04 35.71% 6.7M
|
Technology Services
Your saved searches
Save your searches and get alerts when important news are released.